Audentes Therapeutics, Inc. reported unaudited earnings results for third quarter and nine months ended September 30, 2018. For the quarter, the company’s net loss was $36,291,000 or $0.97 per basic and diluted compared to $25,009,000 or $0.88 per basic and diluted for the same period a year ago. Loss from operations was $37,735,000 compared to $25,210,000 for the same period a year ago. For the nine months, the company’s net loss was $93,229,000 or $2.57 per basic and diluted compared to $65,863,000 or $2.59 per basic and diluted for the same period a year ago. Loss from operations was $96,774,000 compared to $66,296,000 for the same period a year ago.